Companies:
49,998
Total Market Cap:
142307571152351.59
Global Rank
#23900
Country Rank
#1004
Market Cap
115.78 M
Price
1.02
Change (%)
1.21%
Volume
2.31 M
Humasis Co. Ltd.'s latest marketcap:
115.78 M
As of 07/28/2025, Humasis Co. Ltd.'s market capitalization has reached $115.78 M. According to our data, Humasis Co. Ltd. is the 23900th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 115.78 M |
| Revenue (ttm) | 21.44 M |
| Net Income (ttm) | -24,374,464.1 |
| Shares Out | 113.15 M |
| EPS (ttm) | -0.21 |
| Forward PE | 0.00 |
| Ex-Dividend Date | 12/28/2022 |
| Earnings Date | 08/14/2025 |
Market Cap Chart
Data Updated: 07/28/2025
Humasis Co. Ltd.'s yearly market capitalization.
Humasis Co. Ltd. has seen its market value grow from ₩55.84 B to ₩160.45 B since 2017, representing a total increase of 187.35% and an annual compound growth rate (CAGR) of 14.94%.
| Date | Market Cap(₩) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/28/2025 | ₩160.45 B | $115.78 M | -14.42% | 23900 |
| 12/30/2024 | ₩185.23 B | $124.11 M | -22.8% | 21886 |
| 12/28/2023 | ₩239.92 B | $184.74 M | -47.44% | 19284 |
| 12/29/2022 | ₩456.45 B | $360.59 M | -20.07% | 14384 |
| 12/30/2021 | ₩571.04 B | $479.67 M | 75.79% | 13637 |
| 12/30/2020 | ₩324.84 B | $298.86 M | 729.52% | 14588 |
| 12/30/2019 | ₩39.16 B | $33.68 M | 2.31% | 23994 |
| 12/28/2018 | ₩38.28 B | $34.07 M | -31.45% | 22979 |
| 12/28/2017 | ₩55.84 B | $51.93 M | 21351 |
Company Profile
About Humasis Co. Ltd.
Humasis Co. Ltd. is a South Korean company specializing in the manufacturing and sale of pharmaceuticals and medical devices, serving both domestic and international markets.
Product Offerings
- Immunodiagnostic Kits: Quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health solutions.
- Bio-Material Products: Includes COVID-19 nucleocapsid protein, HIV surface proteins, COVID-19 RT-PCR kits, COVID-19 Variant RT-qPCR kits, and MPXV real-time PCR kits for Monkeypox virus detection.
- Diagnostic Equipment: Urinalysis tools, blood glucose meters, and immunodiagnostics devices.
- Other Test Kits: Cotinine (urine testing) and G6PD (glucose-6-phosphate dehydrogenase detection in human whole blood).
Company Background
Founded in 2000, Humasis Co. Ltd. is headquartered in Anyang-si, South Korea.
Frequently Asked Questions
-
What is Humasis Co. Ltd.'s (KOSDAQ-205470) current market cap?As of 07/28/2025, Humasis Co. Ltd. (including the parent company, if applicable) has an estimated market capitalization of $115.78 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Humasis Co. Ltd. (KOSDAQ-205470) rank globally by market cap?Humasis Co. Ltd. global market capitalization ranking is approximately 23900 as of 07/28/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.